Exelixis, Inc. (EXEL) Revenue by Segment

Executive TeamFinancialsSegments
Shareholders

Exelixis revenue by segment at a glance

In Q2 fiscal 2026 (the quarter ended July 3, 2026), Exelixis's largest product or service was Product, with $573.03 million or 91% of revenue, up 10.2% from a year earlier. Next: Collaboration (9%).

By region, United States brought in 92%, Europe brought in 7% and Japan brought in 1% of revenue in Q2 fiscal 2026.

By country, UNITED STATES brought in 92%, Europe brought in 7% and JAPAN brought in 1% of revenue in Q2 fiscal 2026.

The fastest-growing product or service from a year earlier was Collaboration (+15.4%).

From company filings, in USD; latest quarter ended July 3, 2026; quarterly data from Q3 fiscal 2017.

EXEL logo

Exelixis, Inc.

EXELUnited States
Healthcare

Revenue breakdown

Fiscal quarters, from company filings

Exelixis revenue by product or service, last 4 quarters

Product or serviceQ2 FY26Q1 FY26Q3 FY25Q2 FY25Share
Product$573.0M$555.0M$542.9M$520.0M91%
Collaboration$55.7M$55.8M$54.8M$48.2M9%

In USD, fiscal quarters as reported; share = part of Q2 FY26 revenue.

Exelixis revenue by region, last 4 quarters

RegionQ2 FY26Q1 FY26Q3 FY25Q2 FY25Share
United States$578.4M$558.5M$546.5M$524.8M92%
Europe$46.0M$39.6M$45.0M$37.0M7%
Japan$4.3M$12.7M$6.3M$6.5M1%

In USD, fiscal quarters as reported; share = part of Q2 FY26 revenue.

Exelixis revenue by country, last 4 quarters

CountryQ2 FY26Q1 FY26Q3 FY25Q2 FY25Share
UNITED STATES$578.4M$558.5M$546.5M$524.8M92%
Europe$46.0M$39.6M$45.0M$37.0M7%
JAPAN$4.3M$12.7M$6.3M$6.5M1%

In USD, fiscal quarters as reported; share = part of Q2 FY26 revenue.

Questions and answers

Which product or service makes the most money for Exelixis?

Product: $573.03 million, or 91% of revenue, in Q2 fiscal 2026.

What are Exelixis's main products and services?

By revenue in Q2 fiscal 2026: Product (91%) and Collaboration (9%).

Where does Exelixis make its money?

By region in Q2 fiscal 2026: United States (92%), Europe (7%) and Japan (1%).

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.
LinkedInLinkedInXXYouTubeYouTube